Akari Therapeutics, Plc
AKTX
$1.43
-$0.03-2.06%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.05M | 1.71M | 2.24M | 3.71M | 2.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.30M | 1.85M | 5.56M | 5.99M | 5.09M |
| Operating Income | -4.30M | -1.85M | -5.56M | -5.99M | -5.09M |
| Income Before Tax | -3.77M | -2.90M | -7.56M | -5.57M | -4.14M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.77M | -2.90M | -7.56M | -5.57M | -4.14M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.77M | -2.90M | -7.56M | -5.57M | -4.14M |
| EBIT | -4.30M | -1.85M | -5.56M | -5.99M | -5.09M |
| EBITDA | -4.29M | -1.85M | -5.56M | -5.98M | -5.09M |
| EPS Basic | -388.80 | -474.80 | -1.61K | -1.66K | -1.88K |
| Normalized Basic EPS | -0.09 | -0.09 | -0.38 | -0.52 | -0.59 |
| EPS Diluted | -388.80 | -474.80 | -1.61K | -1.66K | -1.88K |
| Normalized Diluted EPS | -0.09 | -0.09 | -0.38 | -0.52 | -0.59 |
| Average Basic Shares Outstanding | 19.41M | 12.19M | 9.42M | 6.73M | 4.40M |
| Average Diluted Shares Outstanding | 9.70K | 6.00K | 4.70K | 3.30K | 2.10K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |